KIT D816G

CI-VAR-00000559Explore in graph →NP_000213.1:p.Asp816GlyNM_000222.2:c.2447A>GClinVar 1968176 CIViC 1402

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Gastrointestinal Stromal Tumor2
KIT D816G	Ponatinib	Predictive	D	Supports Sensitivity Response	4	submitted	EID7410 Ponatinib possesses potent activity against D816G KIT mutant in preclinical experiments. PMID 25239608 · Garner et al., 2014 · Open in CIViC	civic
KIT D816G	Regorafenib	Predictive	D	Supports Resistance	2	submitted	EID4157 In an in vitro study, a Ba/F3 cell line expressing KIT W557_K558del primary mutation (known to confer sensitivity to regorafenib) and KIT D816G secondary mutation, KIT D816G was associated with decrea… (full text at CIViC) PMID 25239608 · Garner et al., 2014 · Open in CIViC	civic
Lung Adenocarcinoma

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.